亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

39P Preliminary clinical investigations and mechanism exploration of furmonertinib in NSCLC with EGFR exon 20 insertion

医学 奥西默替尼 内科学 第一行 肿瘤科 胃肠病学 外科 表皮生长因子受体 癌症 埃罗替尼
作者
X. Zhang,G. Feng,H. Han,B. Dong,Y. Yang,H. Zhu,S. Fan,H. Tang
出处
期刊:Journal of Thoracic Oncology [Elsevier BV]
卷期号:18 (4): S63-S63
标识
DOI:10.1016/s1556-0864(23)00293-9
摘要

Here we analyzed the clinical efficacy of furmonertinib, a novel 3rd generation EGFR TKI, in advanced NSCLC patients (pts) who harboring EGFRex20ins and explored mechanism. A retrospective single-arm analysis was performed to evaluate the efficacy of 20 NSCLC pts harboring EGFRex20ins receiving furmonertinib treatment from three institutions. Meanwhile, we investigated the clinical efficacy of furmonertinib versus osimertinib as second-line treatment, because pts about furmonertinib as first-line treatment were immature. In addition, the binding activity of different EGFR TKIs to EGFRex20ins were computationally constructed based on the crystal structure of EGFR_D770_N771insNPG/V948R (PDB ID: 7LGS) by the Schrödinger software (2021–2 Release). Of the 20 pts selected, we found that EGFRex20ins p. S768_D770dup (n = 5) variants were more common. Six first-line pts all achieved PR (ORR: 100%), five of the eight second-line pts achieved PR (ORR: 62.5%), and three of the six multiple-line pts achieved PR (ORR: 50.0%). We observed 14 pts with PR and six pts with SD as best response to furmonertinib (ORR: 70.0%, DCR: 100%). All pts showed tumor shrinkage in target lesions (median best percent change, –36.43% [–74.78%, –5.56%]). Median PFS was 10.2 (95% CI, 7.19–13.21) months (mo). Median DOR was 8.5 (95% CI, 4.97–12.03) mo. Comparative analysis of the efficacy of different groups showed that median PFS was significantly longer in furmonertinib group than in osimertinib (10.2 vs 3.8 mo, p = 0.008). Median OS was numerically longer in furmonertinib group than in osimertinib (18.9 vs 11.7 mo, p = 0.207). No grade 3 or above adverse events were observed. Furthermore, rather than erlotinib (GlideScore: –5.564; MM/GBSA: –52.8044), gefitinib (–7.68; –47.317), and afatinib (–5.075; –44.64), furmonertinib (–11.085; –68.1575) and osimertinib (–10.031; –63.87) revealed favorable binding activity to EGFRex20ins, with furmonertinib being the most significant. Furmonertinib has positive clinical efficacy to advanced NSCLC pts with EGFRex20ins probably based on its favorable binding activity to EGFRex20ins. Furmonertinib may be the optimal choice for these pts in the future.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
明亮的卿发布了新的文献求助10
5秒前
爆米花应助科研通管家采纳,获得10
8秒前
8秒前
小蘑菇应助科研通管家采纳,获得10
8秒前
上官若男应助明亮的卿采纳,获得10
11秒前
文献菜鸟发布了新的文献求助10
14秒前
量子星尘发布了新的文献求助10
37秒前
43秒前
文献菜鸟完成签到 ,获得积分10
47秒前
59秒前
Michelangelo_微风完成签到,获得积分10
1分钟前
1分钟前
整齐的萝发布了新的文献求助10
1分钟前
1分钟前
火星上的天思完成签到,获得积分10
1分钟前
隐形曼青应助Ultraman45采纳,获得10
1分钟前
2311发布了新的文献求助30
1分钟前
赝品也烂漫完成签到,获得积分10
1分钟前
Asher完成签到,获得积分10
1分钟前
1分钟前
小胡爱科研完成签到 ,获得积分10
1分钟前
003完成签到,获得积分10
1分钟前
1分钟前
duan完成签到 ,获得积分10
1分钟前
2311完成签到 ,获得积分20
1分钟前
2311关注了科研通微信公众号
1分钟前
1分钟前
1分钟前
kento完成签到,获得积分0
1分钟前
fang完成签到,获得积分10
2分钟前
Tumumu完成签到,获得积分10
2分钟前
Li完成签到,获得积分10
2分钟前
fang发布了新的文献求助10
2分钟前
科目三应助科研通管家采纳,获得10
2分钟前
orixero应助科研通管家采纳,获得10
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
共享精神应助科研通管家采纳,获得10
2分钟前
科目三应助科研通管家采纳,获得10
2分钟前
Jasper应助科研通管家采纳,获得10
2分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976643
求助须知:如何正确求助?哪些是违规求助? 3520735
关于积分的说明 11204613
捐赠科研通 3257484
什么是DOI,文献DOI怎么找? 1798716
邀请新用户注册赠送积分活动 877897
科研通“疑难数据库(出版商)”最低求助积分说明 806613